June 2014: OCTO News


SCOT closed to recruitment at the end of Nov 2013. Follow up visits are scheduled until the end of Nov 2014. The primary end-point of the study is disease free survival (3yrs). In view of the patients recruited in the later years of recruitment we are applying for a funding extension to follow all patients to a minimum of the 3 year time point. We expect an outcome to this funding application in approx. 6 to 8 months.

Thanks to all sites for the on-going excellent rate of data return.  Treatment visits for the last recruited patients will finish June / July 2014; sites are requested to ensure all treatment CRFs are returned promptly to OCTO.

TransSCOT sample return continues well. Thanks to all sites which have returned samples. If there are any questions or issues with sample return. Please contact your SCOT co-ordinating office.


Since the randomised phase of the RADVAN trial opened in April 2013 recruitment has been more challenging than expected. this can mostly be attributed to the increased treatment options now available to this patient group since the trial was conceived.

The Trial Steering Committee has therefore agreed to close recruitment to the RADVAN trial as of the 30th April 2014.

We would like to thank everyone for their support of the trial.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.